논문KCI 등재
2025 KASL clinical practice guidelines for management of hepatitis C
4
조회
0
다운로드
0
인용
0
참고문헌
키워드
관련 논문AI추천
2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis CThe Korean Association for the Study of the Liver대한간학회 · Clinical and Molecular Hepatology2018 · 제24권 제3호KASL clinical practice guidelines for management of chronic hepatitis BKorean Association for the Study of the Liver (KASL)대한간학회 · Clinical and Molecular Hepatology2019 · 제25권 제2호KASL clinical practice guidelines for management of chronic hepatitis BThe Korean Association for the Study of the Liver대한간학회 · Clinical and Molecular Hepatology2022 · 제28권 제2호KASL clinical practice guidelines for the management of metabolic dysfunction-associated steatotic liver disease 2025Byoung Kuk Jang, Eun Joo Lee, Gi-Ae Kim, Hye Won Lee, Jeong-ju Yoo, Jung Hee Kim, Miyoung Choi, Pil Soo Sung, Soon Sun Kim, Su Jong Yu, Won Sohn, Young Chang, Young-Joo Jin, Young Kul Jung, Young-Sun Lee대한간학회 · Clinical and Molecular Hepatology2025 · 제31권 제1호KASL clinical practice guidelines for noninvasive tests to assess liver fibrosis in chronic liver diseaseBeom Kyung Kim, Dae Won Jun, Eun Joo Lee, Eun Ju Cho, Han Ah Lee, Hee Yeon Kim, Jihyun An, Ji Won Han, Jung Hwan Yu, Mi Na Kim, Minjong Lee, Moon Young Kim, Sang Gyune Kim, Seung-seob Kim, Seung Up Kim, Young Eun Chon, Young-Joo Jin, YoungRok Choi, Yuri Cho, Yu Rim Shin대한간학회 · Clinical and Molecular Hepatology2024 · 제30권 제1호KASL clinical practice guidelines for management of autoimmune hepatitis 2022The Korean Association for the Study of the Liver (KASL)대한간학회 · Clinical and Molecular Hepatology2023 · 제29권 제3호
이 간행물의 다른 논문 (76건)
Critical considerations in evaluating the therapeutic potential of HK-660S for primary sclerosing cholangi tis: Letter to the editor on “Safety and efficacy of HK 660S in patients with primary sclerosing cholangitis: a randomized double-blind phase 2a trial”Yizi He, Haifeng He, Qi Liang, Yongzhi Xiepp. 1-3Letter to the editor on “Current burden of steatotic liv er disease and fibrosis among adults in the United States, 2017–2023”Sisi Yang, Zhenxuan Mapp. 4-6Letter to the editor on “Direct-acting antiviral therapy for patients with HCV-related hepatocellular carcino ma: a nationwide cohort study”Xiaodi Yang, Zhongqing Qian, Qiong Wang, Fuliang Chen, Xiaojing Wang, Deyan Chenpp. 7-9Letter to the editor on “GULP1 as a novel diagnostic and predictive biomarker in hepatocellular carcinoma”Juan Yang, Xinyi Li, Sheng Zhengpp. 10-12Letter to the editor on “Radiogenomics of intrahepatic cholangiocarcinoma predicts immunochemotherapy response and identifies therapeutic target”Ruiyun Guo, Yuqian Liu, Jun Mapp. 13-15